Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Slip Slide and Away!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by Snowballgrowthon Aug 21, 2020 10:57am
80 Views
Post# 31438265

RE:RE:RE:RE:RE:RE:RE:RE:RE:Slip Slide and Away!

RE:RE:RE:RE:RE:RE:RE:RE:RE:Slip Slide and Away!

indoubtgetout wrote: Jonathan will get his act together and pick up his game or shareholders will dump his stock!!   Frankly, GUD should not be publicly traded company but that said, Jonathan uses GUD as his play toy - he is the President!!!   He really does not care about shareholders - so in the end, Jonathan will continue to be President but GUD stock price and Jonthan's net worth WILL BE ALLOT LOWER THAN IT IS TODAY!  Nobody in their right mind would buy any or more of GUD until GUD management (aka Mr. Jonathan the President) can demonstrate they are doing something that will benefit ALL shareholders.   Don't see that now...

 

ok I see your point of view. Thank you to share. BTW Ms Samira Sakhia is the President of the company. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities